Abeona Therapeutics Inc

Abeona’s initial commercialization focus is the United States, where ZEVASKYN received FDA approval and where the company is establishing a network of Qualified Treatment Centers across the country to reach patients nationwide. The company operates a cGMP commercial manufacturing facility in Cleveland, Ohio to produce ZEVASKYN drug product for launch and ongoing supply. While the product has received orphan designations in the U.S. and the European Medicines Agency has granted Orphan Drug Designation, international expansion depends on additional regulatory approvals and market access execution. Cross-border trade policy, sanctions, and non-tariff measures are relevant because they can affect suppliers, international operations, and the ability to compete or attract non-U.S. partners and resources.

Abeona’s business is highly concentrated in a single newly approved product, so the timing and rate of ZEVASKYN adoption, reimbursement outcomes, and competitive developments can drive large swings in revenue and cash needs. The company faces execution risk in identifying and enrolling RDEB patients, building QTC capacity, and maintaining physician and patient confidence, particularly if safety signals, labeling changes, or negative publicity emerge. Operationally, autologous cell/gene therapy manufacturing is complex; quality failures, supply disruptions, or capacity constraints could lead to shortages and lost demand. Regulatory risk remains material, including potential disruptions at the FDA or other agencies that could delay approvals, post-approval changes, or future pipeline progress, while trade restrictions and sanctions can add compliance cost and limit international options.